The American Invents Act could have a big effect on the life sciences industry. Kevin Matha spoke with Robert A Armitage, senior vice president and general counsel at Eli Lilly, about the new legislative package
Tom Ciotti and Kate Murashige of Morrison & Foerster have been involved with the life sciences industry for almost 50 years. Phillip Bausk spoke with them about the changes they have seen in that time
Edward J Farrington of Inspicos considers the role of human intervention when acertaining the limits of patentability in plant breeding
Louise Tottie and Anette Romare of Valea outline important aspects of selection inventions relating to lists and ranges, to consider when drafting patent applications
Agustín Azcatl, Daniel Sánchez and Pedro Herrera of Olivares & Cia explain the impact of rule changes on first medical-use claims
Ha Kung Wong and John Kirkland of Fitzpatrick Cella Harper & Scinto use three scenarios to examine the impact of the Act and the future of paragraph IV litigation
@schestowitz Well, we do what we think is most appropriate & useful for our readers. Can't speak for others.
@schestowitz It's true that we have sought interviews with AMBA (not specifically on UPC) and permission was refused by the EPO president.
@schestowitz However, we have also given space to voices critical of UPC & Unitary Patent, eg in Spain & Poland https://t.co/QXiPQknzDg
Patent subject matter eligibility: A new Section 101
Calls for changing Section 101 of the Patent Act in the US are increasing. A proposed amendment from IPO shows one way to do it, reports Michael Loney
The material on this site is for financial institutions, professional investors
and their professional advisers. It is for information only. Please read our
Terms and Conditions
before using the site. All material subject to strictly enforced copyright laws.
© 2017 Euromoney Institutional Investor PLC. For help please
see our FAQ.
Switching to MIP International